A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
Completed · Phase 1 · Has a placebo group
Conditions studied: Nonalcoholic Fatty Liver Disease
In brief
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in healthy non obese subjects and subjects with NAFLD.
Key facts
- Study ID
- NCT03998514
- Run by
- CohBar, Inc.
- People needed
- 88
- Starts
- 2018-07-09
- Expected to finish
- 2021-04-19
- Last updated by the study team
- 2021-05-11
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- ProScietno — Chula Vista, California, United States
- Covance Clinical Research Unit Inc. — Dallas, Texas, United States
- The Texas Liver Institute — San Antonio, Texas, United States
- Endeavor Clinical Trials, LLC — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.